PPT-Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6

CEDGE Treatment Naïve TN Phase 3 Treatment Naïve Zeuzem S et al Ann Intern Med 2015163113 Source Zeuzem S et al Ann Intern Med 2015163113 ElbasvirGrazoprevir. Mark Sulkowski, MD . Professor of Medicine. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/ Hepatology. Johns Hopkins Medical Institutions. Baltimore Maryland USA. Mark S. Sulkowski, MD. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/Hepatology. Johns Hopkins University School of Medicine. Baltimore, Maryland. Treatment-Naive Data . Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. . +/- Ribavirin in HCV Genotype 1, 4 or 6. C-EDGE Treatment Experienced (TE). Phase 3. . Treatment. . Experienced. Kwo. P, . et al. . EASL 2015. Abstract P0886.. Source: . Kwo. P et al. EASL 2015. Abstract P0886.. X. J . Hepatology. 2015; 63: 564-72. C-SALVAGE Study: . grazoprevir. . + . elbasvir. + RBV in genotype 1 with failure to PI-based regimen. NS3 and NS5A RAVs identified by population sequencing at baseline and VF. in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. 6; 386:1537-45. C-SURFER Study: . grazoprevir. . + . elbasvir. . in genotype 1 with chronic kidney disease. N = 111. GZR + EBR. Placebo. GZR + EBR (Intensive PK). N = 113. N = 11. GZR/EBR. W. 12. W16. ASTRAL-2*. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-3 Trial. Source: Foster GR, . et al. N . Ribavirin in PI-experienced HCV GT1. C-SALVAGE. Phase . 2 . Treatment. . Experienced. (1) . Buti. M, et al. . Clin. Infect Dis. 2016;62:32-6. (2) . Forns. X, et al. J . Hepatol. . 2015;63:564-72. ASTRAL-1. Phase 3. . Treatment. . Naïve & Experienced. Feld JJ, . et al. . N . Engl. J Med. . 2015. ;373:2599-607.. Source: Feld . JJ. , et al. N . Engl. J Med. . 2015. ;373:2599-607.. Sofosbuvir-Velpatasvir. . Case. 47-Year-Old . Man With Asymptomatic HIV Infection. Case (cont). Initial Clinical Presentation. Laboratory Results. HepaScore. ®. A Composite Biomarker Panel for Liver Fibrosis. Hepatic Steatosis in Patients With HIV/HCV Coinfection. OPTIMIZE (. Study . C211). Phase . 3. Treatment. . Naïve. Buti. M, et al. Gastroenterology. 2013 Dec 4. [. Epub. ahead of print]. Source: . Buti. M, et al. Gastroenterology. 2013 Dec 4. [. Epub. HCV . GT 1,4, or 6 in PWID* on Opiate Agonist Therapy. C-EDGE CO-STAR. Phase . 2. Treatment. . Naïve. Dore G, . et al. . AALSD. 2015; Abstract 40. . Injection Drug Use. *PWID = Persons . W. ho . I. Dr. Sonalika’s Eye Clinic provide the best Conjunctivitis (Pink Eye) treatment in Pune, Hadapsar, Amanora, Magarpatta, Mundhwa, Kharadi Rd, Viman Nagar, Wagholi, and Wadgaon Sheri